A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

Abstract Background The development of immune checkpoint inhibitors has made a significant breakthrough in the treatment of non‐small‐cell lung cancer (NSCLC). However, there remains a huge unmet clinical need for patients with acquired resistance after initial treatment response. Methods This study...

Full description

Bibliographic Details
Main Authors: Yuguang Zhao, Xiao Chen, Jun Yao, Jianlin Long, Yong Mao, Di Wu, Aimin Zang, Jun Zhao, Ziling Liu, Rui Meng, Ye Chen, Yang Luo, Qun Guo, Li Li, Jiuwei Cui
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.6855

Similar Items

Similar Items